课题基金 / 基金详情

项目摘要

项目成果

MACIEJ S LESNIAK的其他基金

相似基金

相关文献

中文摘要
翻译
实验研究报告:摘要 DRP是Brain SPORE的重要组成部分,每年为3-4个项目提供支持, 平移势资金是灵活的,支持项目的期限为两年或更短。 DRP调查人员将充分发展他们的试点项目,以取代已经达到的主要项目, 结论,或者没有进展。如果没有这样的需要,将鼓励DRP项目调查员 通过R 01机制获得独立资金。DRP将在整个 项目期间; SPORE资金将与机构支持相匹配。 与西北大学合作, 卢里癌症中心的脑肿瘤研究所,将有一个高度结构化的征集过程, 审查和评价试点项目;大力鼓励妇女和少数民族调查员提出申请。 《残疾人权利方案》的具体目标是: 目标1。征集、识别和支持被认为具有以下价值的优秀转化研究项目: 影响脑肿瘤的诊断和/或治疗和/或预防的可能性很高。 目标2.促进开发项目成熟为完整的SPORE项目或独立资助的项目 项目 目标3.为了吸引优秀的新的和有经验的研究人员目前没有工作的脑肿瘤, 从事脑肿瘤研究,特别强调支持妇女和少数民族研究人员。
英文摘要
DEVELOPMENTAL RESEARCH PROGRAM: SUMMARY The DRP is an essential component of the Brain SPORE, providing yearly support to 3-4 projects that have translational potential. Funding is flexible, supporting projects for a period of two years or less. It is expected that DRP investigators will develop their pilots sufficiently to either replace main projects that have reached conclusion, or are not progressing. If there is no such need, DRP project investigators will be encouraged to secure independent funding, such a through the R01 mechanism. The DRP will be maintained for the entire project period; SPORE funds will be matched by Institutional support. In collaboration with the Northwestern's Brain Tumor Institute at the Lurie Cancer Center, there will be a highly structured process for solicitation, review and evaluation of pilot projects; women and minority investigators will be strongly encouraged to apply. The specific aims of the DRP are: Aim 1. To solicit, identify and support meritorious translational research projects that are considered as having a high probability of impacting the diagnosis and/or treatment and/or prevention of brain tumors. Aim 2. To facilitate developmental project maturation into full SPORE projects or independently funded projects. Aim 3. To attract outstanding new and experienced investigators currently not working on brain tumors to pursue brain tumor research, with a special emphasis on supporting women and minority investigators.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Arginine Metabolism Regulates Myeloid Immune Suppression in Glioblastoma
phase 1 adaptive dose-escalation study of mycophenolate mofetil (MMF) in combination with temozolomide (TMZ) for patients with newly diagnosed glioblastoma
Arginine Metabolism Regulates Myeloid Immune Suppression in Glioblastoma
SPORE for Translational Approaches to Brain Cancer
海外基金